

Diagnosis and Management of Adult Bacterial Meningitis

Wen-Neng Chang and Chen-Hsien Lu

Abstract- The early use of appropriate antibiotic therapy is one of the important and explicit steps in the management of potentially fatal adult acute bacterial meningitis (ABM). Changing epidemiology of ABM, especially with regards to the change of the relative frequency of causative pathogens, has been noted in a series of studies in Taiwan. This change may influence the choice of initial empiric antibiotic treatment. In this review, the authors will discuss the epidemiologic trend, diagnosis and management of ABM in Taiwan. For a better understanding, the clinical and laboratory data of 204 adult ABM cases diagnosed at Chang Gung Memorial Hospital-Kaohsiung, collected over a period of 8 years (1999-2006), were included for analysis. This review may help first-line, primary-care neurologists have a better view on handling this critical central nervous system infection.

Key Words: Adult, Acute bacterial meningitis, Diagnosis, Epidemiologic trend, Management

Acta Neurol Taiwan 2009;18:3-13

INTRODUCTION

Acute bacterial meningitis (ABM) in adults is a serious infectious disease of the central nervous system (CNS)^(1,2). Despite the availability of effective antibiotics and the advent of new antibiotics, adult ABM remains a disease of high mortality and morbidity. A delay in early appropriate antibiotic treatment has been associated with worse outcomes. For this critical issue, neurologists are often called on to “rule out” ABM, therefore, a dilemma exist for neurologists who need to accurately diagnose patients with ABM and then rapidly administer appropriate management (antibiotics, adjunctive steroid and/or neurosurgical procedures) for this potentially

fatal disease.

In adult ABM patients, little is known about the exact timeframe between the initial onset of symptoms and first visit with a neurologist. Patients in a postneurosurgical state, in that they have had a preceding event such as a brain condition, may have overlapping signs and symptoms of meningitis and this results in a greater difficulty in making a proper ABM diagnosis. Meanwhile, although acute meningitis is usually caused by bacteria or viruses, some pathogens of chronic meningitis such as fungi may have similar clinical presentations. The following two cases are clinical examples of common and uncommon acute meningitis.

Case 1, a 38-year-old man, presented to the emer-

From the Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Received December 3, 2008.
Revised and Accepted December 5, 2008.

Reprint requests and correspondence to: Wen-Neng Chang MD. Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung, No. 123, Ta Pei Road, Niao Sung Hsiang, Kaohsiung Hsien 833, Taiwan.
E-mail: cwenneng@ms19.hinet.net

gency room (ER) of Chang Gung Memorial Hospital-Kaohsiung with a chief complaint of headache, fever and vomiting for 5 days. His past history was unremarkable. Except for the presence of neck stiffness, all other neurologic examinations revealed normal results. Under the impression of acute meningitis, blood and cerebrospinal fluid (CSF) studies were performed and the results revealed peripheral leukocytosis (WBC $21.6 \times 10^3/\text{mm}^3$) and purulent CSF profile including WBC $1485/\text{mm}^3$ (neutrophil 90%), glucose $< 5 \text{ mg/dL}$, and total protein (TP) 714.3 mg/dL . Leptomeningeal enhancement was detected on brain magnetic resonance imaging (MRI) study and multiple liver abscesses were detected on both abdominal echo and computed tomogram (CT) study. Cultures of CSF, blood and pus aspirated from liver abscess grew *K. pneumoniae*. For these infectious problems, this patient received intravenous ceftriaxone (2 gm Q12 hr) therapy and a drainage for liver abscess.

Case 2, a 56-year-old man with diabetes mellitus (DM) and liver cirrhosis, present to the ER with a chief complaint of headache and fever for one day and altered consciousness for half day. Brain MRI study revealed leptomeningeal enhancement and hydrocephalus. CSF study showed leukocytosis (WBC $550/\text{mm}^3$), glucose 94 mg/dL and TP 75 mg/dL . A CSF cryptococcal antigen detection revealed a positive result (1:512). This patient was treated with amphotericin B and fluconazole.

For these clinical problems, this review article will focus on the diagnosis and management of adult ABM. Furthermore, the clinical data of 204 adult ABM cases, diagnosed at Chang Gung Memorial Hospital Kaohsiung, collected over a period of 8 years (1999-2006) were included for analysis. The clinical and laboratory data of these patients are shown in Tables 1-5.

IMPLICATED PATHOGENS

One of the important issues that the neurologists have to face is the changing epidemiologic trend of adult ABM in recent years⁽¹⁻¹⁶⁾. This change may influence the choice of initial empiric antibiotic treatment⁽¹⁾ which is an important strategy for a successful treatment of adult

ABM. The prevalence rate of implicated pathogens of ABM is influenced by several factors including age, preceding medical and/or surgical conditions, mode of contraction, geographic distribution, status of vaccination, and the time period of study. For example, *Hemophilus influenzae* type b has nearly been eliminated in many developed countries since routine childhood vaccination was initiated⁽¹⁷⁾. The same is true for both *Streptococcus pneumoniae* and *Neisseria meningitidis* infections in some regions of the world⁽¹⁸⁻²¹⁾.

Table 1 shows the implicated pathogens of the 204 enrolled ABM cases. The listed relative frequency of implicated pathogens of adult ABM is quite different from those reported in western countries^(1-5,22). 185 of these 204 cases involved monomicrobial infection (Gram-negative infection 110, Gram-positive infection 75) and 19 mixed infections. The leading implicated Gram-negative and Gram-positive pathogens were *K. pneumoniae* and staphylococcal species, respectively. Among the implicated pathogens, *K. pneumoniae* is still the most common, accounting for 24.9% (46/185) of monomicrobial infection. This finding is consistent with previous studies of adult ABM in Taiwan⁽²²⁻²⁴⁾. Compared with other adult ABM cases, *K. pneumoniae* meningitis is usually a spontaneous, community-acquired infection and most of these cases involve DM and/or liver disease as the underlying conditions^(1,22-25). Concomitant septic metastatic infection is also common in this specific adult ABM in Taiwan⁽²⁶⁾ and usually requires a drainage procedure during the therapeutic course.

Acinetobacter (*A.*) *spp.*, *Escherichia* (*E.*) *coli*, *Pseudomonas* (*P.*) *spp.* and *Enterobacter* *spp.* are the other frequent Gram-negative pathogens, accounting for 11.4% (21/185), 7.0% (13/185), 6.5% (12/185) and 3.8% (7/185), respectively for adult ABM of a monomicrobial infection. They are all frequent pathogens of ABM patients with a posneurosurgical state^(1,27-33). Our previous study⁽³⁴⁾ showed that *Acinetobacter* meningitis accounted for 3.3% of monomicrobial ABM, but its incidence has increased markedly and has replaced *Pseudomonas* ABM as the second most common Gram-negative ABM. The emergence of *Acinetobacter* infection and the frequent multiple antibiotic resistant feature of

Table 1. Causative pathogens of 204 adult bacterial meningitis cases

Gram-negative pathogens	Gram-positive pathogens	Mixed infection
<i>Klebsiella pneumoniae</i> (46)	<i>Coagulase-negative staphylococci</i> (24)	(19)
<i>Acinetobacter species</i> (21)	<i>Staphylococcus aureus</i> (20)	
<i>Escherichia coli</i> (13)	<i>Viridans streptococci</i> (8)	
<i>Pseudomonas species</i> (12)	<i>Streptococcus pneumoniae</i> (7)	
<i>Enterobacter species</i> (7)	<i>Enterococcus species</i> (7)	
<i>Proteus mirabilis</i> (3)	<i>Others streptococci</i> (3)	
<i>Neisseria meningitidis</i> (2)	<i>Corynebacterium species</i> (3)	
<i>Salmonella species</i> (2)	<i>Listeria monocytogenes</i> (2)	
<i>Fusobacterium necleatum</i> (1)	<i>Micrococcus</i> (1)	
<i>Sphingomonas paucimobilis</i> (1)		
<i>Serratia marcescens</i> (1)		
<i>Citrobacter diversus</i> (1)		

Acinetobacter strains such as the emergence of pan-drug resistant *A. baumannii* strain have resulted in increased therapeutic difficulty^(28,29). The emergence of 3rd- and 4th-generation cephalosporin-resistant strains in implicated *E. coli*, *Pseudomonas spp.* and *Enterobacter spp.* is also a therapeutic challenge of adult ABM⁽³⁰⁻³³⁾. Mixed infection accounted for 9.3% (19/204) of our study group. This type of infection is usually seen in patients with a postneurosurgical state⁽³⁵⁾ and its incidence did not change when compared with the incidence of mixed infections in our previous study⁽³⁴⁾.

With regards to the Gram-positive pathogens, Table 1 shows a marked increase in the incidence of staphylococcal infection and a decrease in the incidence of *Streptococcus pneumoniae* infection when compared with the data of our previous report⁽³⁴⁾. *Staphylococcal spp.* accounted for 23.8% (44/185) of the implicated pathogens of the monomicrobial ABM. Adult staphylococcal infection is frequently noted in patients with a postneurosurgical state, especially in those with an insertion of an intracranial device such as ventriculo-peritoneal shunt and extra-ventricular device⁽³⁶⁻³⁸⁾. The increase of staphylococcal infection can be explained by the increased number of patients with a post-neurosurgical state as their preceding event (Tables 2 and 3, 58.8%, 120/204). Most of the implicated staphylococcal strains of adult ABM are methicillin-resistant⁽³⁶⁻³⁸⁾ and may also

Table 2. Underlying conditions of 204 adult bacterial meningitis cases

	Spontaneous form n = 84	Post-neurosurgical form n = 120
Diaetes mellitus	36	20
Liver disease	14	2
Alcoholism	14	4
Chronic otitis media	5	1
Intravenous drug abuser	5	0
End state renal disease	6	0
Systemic lupus erythematosus	1	1
Malignancy	6	10

Table 3. Preceding neurosurgical conditions of 120 acute bacterial meningitis cases

Postneurosurgical conditions	Case number
s/p V- P shunt	32
s/p EVD	32
s/p craniectomy	19
Spontaneous ICH s/p craniotomy s/p EVD	6
Head trauma s/p craniotomy	6
Head trauma	28
Traumatic ICH s/p EVD, craniectomy, V-P shunt	25

s/p: post-state; V-P: ventriculoperitoneal; EVD: external ventricular device; ICH: intracerebral hemorrhage

cause a therapeutic challenge in the choice of initial empiric antibiotics in adult patients with postneurosurgical meningitis. All of these findings may disclose that despite the in-hospital isolation procedures for patients with methicillin-resistant staphylococcal infection, the increasing incidence in recent years suggests the evidence of rapid dissemination of staphylococcal strains with classic oxacillin resistance, especially in patients with nosocomial infection, in Taiwan⁽³⁷⁻⁴¹⁾. *Streptococcus pneumonia* is an important leading pathogen of ABM, especially in those with spontaneous, community-acquired infection^(2,22,34,42), but its incidence has decreased recently in our comparative studies of epidemiologic trends of adult ABM^(1,34). The exact cause of this decrease is not clear, but it can be explained partially by the increase in nosocomial, post-neurosurgical adult ABM in our study group. The contribution of pneumococcal vaccination in Taiwan in this decrease needs further clarification.

EVALUATION OF SUSPECTED ADULT BACTERIAL MENINGITIS

A. Patient history and clinical presentations

The approach to a patient suspected of having acute

meningitis begins with an evaluation of the clinical history. However, the clinical course and classic presentations including fever, headache, meningismus, and altered consciousness have a poor sensitivity and specificity for the diagnosis of ABM. As shown in Table 4, fever is the most common finding of adult ABM cases (87.5, 178/204) which is consistent with the findings of other reports^(2,22). However, the lack of a fever response can be seen in patients who are elderly, immunocompromised, or in a partially-treated state. The findings of physical examinations including skin rash, Kerning's sign, Brudzinski's sign, meningismus, and impaired jolt acceleration testing are also non-specific for ABM. Despite this poor correlative state, at least one of the above-mentioned essential elements (fever, headache, meningismus, altered consciousness) is present in 99% of the adult ABM patients⁽⁴³⁾ which may tell us that certain aspects of history and physical examination can be used to heighten suspicion of meningitis even if they cannot alone rule out the diagnosis. Therefore, neurologists should not rely on any single clinical feature or single physical test for ABM diagnosis, but should combine a number of historical and physical examination findings together to form a clinical impression.

Table 4. Clinical manifestations of 204 acute bacterial meningitis cases

	Spontaneous meningitis n = 84 (%)	Post-neurosurgical meningitis n = 120 (%)
Fever	76 (90.4)	102 (85.0)
Altered consciousness	56 (66.7)	68 (57.7)
Bacteremia	33 (39.3)	23 (19.2)
Seizure	27 (32.1)	32 (26.7)
Brain abscess	13 (15.5)	8 (6.7)
Hydrocephalus	12 (14.3)	78 (65.0)
Septic shock	9 (10.7)	11 (9.2)
Liver abscess	7 (8.3)	0 (0.0)
Multiple septic abscess	3 (3.6)	3 (2.5)
HHNK or DKA	5 (6.0)	3 (2.5)
Cerebral infarction	3 (3.6)	15 (12.5)
Infections endocarditis	2 (2.4)	0 (0.0)

HHNK: hyperosmolar hyperglycemic non-ketoacidosis; DKA: diabetic ketoacidosis.

B. Neuroimaging study also plays a crucial role in diagnosis and therapeutic decision-making

Unless the capabilities and accessibility of MRI can be expanded, cranial CT scan is used for the evaluation of patients with suspected ABM in most institutions. Cranial imaging can be considered as a way to evaluate for signs of brain shift as a precaution in selected patients before lumbar puncture (LP). It has become common practice to perform cranial CT before performing LP in patients with suspected bacterial meningitis, owing to a perception that this is a standard of care; however, waiting and performing this procedure may delay the start of appropriate antimicrobial therapy⁽⁴⁴⁾. Actually the diagnostic sensitivity of CSF should not be diminished by delaying the LP by 1 or 2 hours after initiating antibiotic therapy⁽⁴⁵⁾. Therefore, patients identified as high risk of brain herniation should have blood drawn for cultures and appropriate empiric antibiotic therapy initiated before undergoing a cranial CT study. But in patients with the following conditions: new-onset seizures, an immunocompromised state, signs of increased intracranial pressure or focal neurologic deficit, or moderate to severe impairment of consciousness, a cranial imaging study should be performed before LP in order to avoid cerebral herniation⁽⁴⁶⁾.

Cranial CT and MRI studies in adult patients with ABM may also reveal the following findings: skull pathology (operation wound, fractures, inner ear infection, mastoiditis, sinusitis), leptomeningeal enhancement, hydrocephalus, cerebral edema, epidural or subdural effusion, abscess, vasculitis and vascular events such as cerebral infarct and venous thrombosis^(1,34,47). For each different neuroimaging finding, a different therapeutic strategy should be considered.

C. CSF analysis is the cornerstone of diagnosis and management of bacterial meningitis

Despite advances in medical science, CSF analysis is the cornerstone of ABM diagnosis and the identification of infectious agents in ABM remains highly dependent on it. Although different sensitivity rates have been reported, both Gram's stain and culture may indicate implicated pathogens in 60% to 90% of ABM cases^(1,2,22,43,48,49) and can certainly help to make the diagno-

sis of ABM with a high specificity if contamination can be excluded. In Taiwan, the problem of staphylococcal contamination of CSF samples should be emphasized as an important local issue due to the high incidence and rise of staphylococcal ABM among postneurosurgical adults⁽³⁶⁻³⁸⁾. Therefore, the diagnosis of such infections should be defined in a very strict manner^(1,2,15,36-38). It is also worth noting that partial antibiotic treatment may alter CSF characteristics and may also decrease the diagnostic yield of Gram's stain and cultures. Although we do not have exact data regarding this important therapeutic issue, the partially treated state of adult ABM should be kept in mind while managing this critical CNS infectious disease. Among CSF profiles, CSF protein level is the most resistant to rapid change, with treatment remaining elevated for 10 days or more^(48,50). Glucose ratio is usually < 0.4 or < 2.5 mmol/l if no simultaneous blood glucose level is determined^(1,51). However, when reading the glucose level data, we must keep in mind that changes in the blood glucose level are reflected in parallel changes in the CSF glucose level. A variable time is required before the CSF glucose level reaches a steady-state equilibrium⁽⁵²⁾. Thus, the CSF glucose level at any moment is a complex function of the blood glucose level. Therefore, when the blood glucose level is of great diagnostic importance, CSF and blood glucose should be obtained simultaneously with the patient in a fasting state for at least 4 hours⁽⁵²⁾. The study of lactate levels in CSF is generally nonspecific in meningitis⁽⁵¹⁾ because the overlapping CSF lactate concentrations seen in different meningitis have limited the value of the assay as a diagnostic test. However, it has been reported that a CSF lactate concentration determination was found to be superior to the glucose ratio for the diagnosis of bacterial meningitis following surgery⁽⁵³⁾.

In ABM, purulent CSF feature (leukocytosis with predominant polymorphonuclear cells) is the most important diagnostic finding^(1,2). Although 90% of patients will have a greater than 100 WBC/mm³ in CSF study and about 60% have a greater than 1000 WBC/mm³^(1-3,49,54,55), 5%-19% of patients still have a CSF WBC count less than 100 WBC/mm³ - a level many would consider predictive for viral disease. The great variability of CSF WBC count is also shown in the 204

Table 5. Prognostic factors of 204 adult bacterial meningitis cases

	Fatal group (N = 64)	Non-fatal group (N = 140)	OR	95 % CI	P-Value
Age at meningitis (year)	58.1 ± 14	51.8 ± 17.3			0.013
Gender					
Female	16	43	0.752	0.385 ± 1.47	0.404
Male	48	97			
Clinical feature					
Fever	55	123	1.184	0.497 ± 2.821	0.703
Disturbed consciousness	45	80	0.563	0.299 ± 1.059	0.073
Seizure	20	39	0.85	0.446 ± 1.619	0.62
Septic shock	17	3	0.061	0.17 ± 0.216	0
Hydrocephalus	26	64	1.231	0.676 ± 2.242	0.497
DKA/HHNK	3	5	0.753	0.174 ± 3.252	0.708
CSF leakage	2	8	1.879	0.388 ± 9.109	0.728
Infectious endocarditis	1	1	0.453	0.028 ± 7.363	0.53
Acquisition of infection					
Community acquired	42	68	0.495	0.268 ± 0.913	0.023
Nosocomial acquired	22	72			
Types of infection					
Spontaneous meningitis	35	49	0.446	0.244 ± 0.815	0.008
Postneurosurgical meningitis	29	91			
GCS at the time of admission	8.4 ± 4.4	9.9 ± 4.3			0.014
Underlying diseases					
Diabetes mellitus	18	38	0.952	0.492 ± 1.842	0.884
Liver cirrhosis	9	8	0.37	0.136 ± 1.01	0.45
Alcoholism	7	11	0.694	0.256 ± 1.883	0.472
Chronic otitis media	3	3	0.445	0.87 ± 2.269	0.38
Intravenous drug abuser	2	3	0.679	0.111 ± 4.165	0.65
End-stage renal disease	5	1	0.085	0.1 ± 0.742	0.012
Systemic lupus erythematosus	1	1	0.453	0.028 ± 7.363	0.53
Malignancy	8	8	0.424	0.152 ± 1.187	0.094
Peripheral blood study					
Thrombocytopenia	4	4			
Bacteremia	25	31			
Leukocytosis	45	89			
Laboratory data at the time of admission					
Glucose (mmol/L)	2.8 ± 2.95	3.06 ± 2.9			0.284
Total Protein (g/L)	5.65 ± 7.16	3.03 ± 3.77			0.002
Lactate (mmol/L)	13.7 ± 8.02	9.97 ± 7.95	0.001		
White cell count (× 10 ⁶ /L)	23472 ± 100597	2503 ± 5689			0.063

GCS: Glasgow coma score; HHNK: hyperosmolar hyperglycemic nonketotic coma; DKA: diabetic ketoacidosis, OR: odds ratio; CI: confidence interval.

enrolled cases (Table 5). Therefore, in the setting of an elevated WBC count in CSF, there is no single variable that can reliably rule out ABM. Neurologists should rely on combinations of CSF findings to accurately predict ABM. In ABM diagnosis, bacterial antigen study with latex agglutination test is not routinely recommended because of its wide-range of susceptibilities and the presence of false-positive results⁽⁵¹⁾. Bacterial DNA detection by polymerase chain reaction for common pathogens in CSF is available^(51,56). Use of broad-range real-time PCR and DNA sequencing has an even higher diagnostic rate of ABM^(57,58). In Taiwan, the value of this genetic study in ABM diagnosis needs further large-scale study for a better delineation.

MANAGEMENT OF BACTERIAL MENINGITIS

The main therapeutic strategies of adult ABM^(1,51,59-61) include 1) use of appropriate antibiotic(s); 2) application of neurosurgical procedures for certain conditions such as hydrocephalus and focal suppuration, and 3) use of anti-inflammatory therapy.

Since host immune response is incapable of controlling infection in the CNS, mandating the use of bactericidal antimicrobial in the treatment of ABM is required⁽⁶²⁻⁶⁴⁾. There is no doubt that reducing mortality and morbidity of ABM is critically dependent on rapid diagnosis and on the timely initiation of appropriate antibiotics. But no bacterial disease has undergone a more dramatic change in epidemiology during the past decade than ABM⁽⁶⁵⁾ and this may influence the choice of initial appropriate empiric antibiotics⁽¹⁾. Empiric therapy of ABM must consider the most likely pathogens involved. Therefore, knowing the epidemiologic trend of ABM is important for antibiotic choice⁽¹⁾. According to a hospital-based study^(1,15,16,24,25,29,30,32-38), the present, important epidemiologic trends of ABM in Taiwan are as follows:

1. There is an increase in incidence of postneurosurgical ABM
2. *K. pneumoniae* is still the most common implicated pathogen of overall adult ABM
3. In Gram-negative adult ABM, there is a marked increase of *Acinetobacter* meningitis and this is

noted especially in patients with a postneurosurgical state

4. In Gram-positive adult ABM, there is also a marked increase in staphylococcal infection in patients with a postneurosurgical state and most of them are methicillin-resistant strains

Because of these practical problems, it is essential that one considers the events preceding ABM when making the choice of initial, empiric antibiotics with a broad-spectrum coverage of the implicated pathogens. In Taiwan, it would be inappropriate to use ceftriaxone as the initial empiric antibiotic to cover all types of adult ABM, especially in those with a postneurosurgical state as the preceding event because in this group of adult ABM, most of the patients have methicillin-resistant staphylococcal infection or multiple antibiotic resistant Gram-negative infection. Therefore, at this moment, initial empiric antibiotics including vancomycin or linezolid plus ceftazidime or cefepime or meropenem would be more appropriate for this specific group of patients. With this combination, most of the implicated pathogens of postneurosurgical ABM patients can have better coverage. Other antibiotic therapy such as the use of ampicillin in old-aged and/or immunocompromised patients should be also considered⁽⁵⁹⁾. So far, ceftriaxone can only be chosen as one of the initial empirical antibiotics in community-acquired ABM patients without an immunocompromised and/or postneurosurgical state. The final antibiotic regimen should be adjusted further by the results of pathogen identification and antibiotic susceptibility test.

Excessive inflammation contributes to the pathogenesis of ABM, therefore, anti-inflammatory drugs have important therapeutic potential, and clinical trials have revealed that early treatment with dexamethasone significantly reduces mortality and morbidity from some groups of adult ABM, especially in those with community-acquired *Streptococcus pneumoniae* infection⁽⁶⁶⁻⁷⁰⁾. But because of different epidemiologic trends, it is uncertain whether all adults with ABM benefit from treatment with adjunctive dexamethasone^(66,71,72). At present there is no related data from Taiwan and therefore, the early use of dexamethasone (dexamethasone given before or with the first dose of antibiotic and then very 6 hours for 4

days)⁽⁶⁰⁾ in adult ABM should be considered with a degree of caution. This concern is primarily related to the high incidence of postneurosurgical conditions as the preceding event and high incidence of DM as the underlying condition among the adult ABM patients^(1,22). If early dexamethasone therapy is used, a more close monitoring of metabolic derangement should be arranged. On the other hand, use of dexamethasone may significantly decrease the achievement of therapeutic vancomycin concentrations in the CSF because its penetration into the CNS is largely dependent on meningeal inflammation^(73,74). There have been clinical studies conducted regarding this therapeutic issue, but the observational results were quite controversial^(75,76). According to the study results of Richard et al.⁽⁷⁶⁾, appropriate concentrations of vancomycin in CSF may be obtained when concomitant steroids are used, providing that vancomycin dosage is "adequate".

The therapeutic result of ABM can be influenced by several factors^(1,22,77). As shown in Table 5, the potential prognostic factors of the 204 ABM adults were many. Different prognostic factors were reported in the literature^(1,2,22). As reported by Lu, et al., serial CSF 14-3-3 protein, especially the gamma isoform, check-ups can be of value in predicting the outcome of community-acquired adult ABM⁽⁷⁸⁾. In their study, most of the ABM patients who survived had nearly cleared their 14-3-3 protein from CSF before discharge. However, thus far, when treating adult ABM patients, the early use of appropriate antibiotics still the most consistent positive prognostic factor.

CONCLUSIONS

For a better therapeutic result, the epidemiologic trends of adult ABM should be examined frequently because any change may influence the choice of initially empiric antibiotic greatly. The therapeutic strategies discussed in this review article may help neurologists, especially first-line primary-care neurologists, to have a better understanding of adult ABM in Taiwan and its management.

REFERENCES

1. Chang WN, Lu CH, Huang CR, et al. Changing epidemiology of adult bacterial meningitis in southern Taiwan: a hospital-based study. *Infection* 2008;36:15-22.
2. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. *N Engl J Med* 1993;328:21-8.
3. Sigurdardottir B, Bjönsson OM, Jonsdottir KE, et al. Acute bacterial meningitis in adults. A 20-year overview. *Arch Intern Med* 1997;157:425-30.
4. Hosoglu S, Ayaz C, Geyik MF, et al. Acute bacterial meningitis in adults: analysis of 218 episodes. *Ir J Med Sci* 1997; 166:231-4.
5. Kyaw MH, Christie P, Jones IG, et al. The changing epidemiology of bacterial meningitis and invasive non-meningitic bacterial disease in Scotland during the period 1983-88. *Scand J Infect Dis* 2002;34:289-98.
6. Chan YC, Wilder-Smith A, Ong BK, et al. Adult community acquired bacterial meningitis in a Singaporean teaching hospital. A seven-year overview (1993-2000). *Singapore Med J* 2002;43:632-6.
7. Khawnnimit B, Chayakul P, Geater A. Acute bacterial meningitis in adults: a 20 year review. *Southeast Asian J Trop Med Public Health* 2004;35:886-92.
8. Perrocheau A, Georges S, Laurent E. Epidemiology of bacterial meningitis in France in 2002. *Rev Prat* 2004;54:945-50.
9. Hui AC, Ng KC, Tong PY, et al. Bacterial meningitis in Hong Kong: 10-years' experience. *Clin Neurol Neurosurg* 2005;107:366-70.
10. Rosinska M, Stefanoff P. Meningitis and encephalitis in Poland in 2003. *Przegl Epidemiol* 2005;59:241-51.
11. Bekondi C, Bernede C, Passone N, et al. Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. *Int J Infect Dis* 2006;10:387-95.
12. Gjini AB, Stuart JM, Lawlor DA, et al. Changing epidemiology of bacterial meningitis among adults in England and Wales 1991-2002. *Epidemiol Infect* 2006;134:567-9.
13. Bouadma L, Schortgen F, Thomas R, et al. Adults with spontaneous aerobic Gram-negative bacillary meningitis admitted to the intensive care unit. *Clin Microbiol Infect*

- 2006;12:287-90.
14. Palabiyikoglu I, Tekeli E, Cokca F, et al. Nosocomial meningitis in a university hospital between 1993 and 2002. *J Hosp Infect* 2006;62:94-7.
 15. Tsai MH, Lu CH, Huang CR, et al. Bacterial meningitis in young adults in southern Taiwan: clinical characteristics and therapeutic outcomes. *Infection* 2006;34:2-8.
 16. Chang CC, Lu CH, Hung CR, et al. Culture-proven bacterial meningitis in elderly patients in southern Taiwan: clinical characteristics and prognostic factors. *Acta Neurol Taiwan* 2006;15:84-91.
 17. Peltola H. Worldwide *Hemophilus influenzae* type b disease at the beginning of 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev* 2000;13:302-17.
 18. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med* 2003;384:1737-46.
 19. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *N Engl J Med* 2006;354:1455-63.
 20. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. *Lancet Infect Dis* 2005;5:21-30.
 21. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2005;54:1-21.
 22. Tang LM, Chen ST, Hsu WC, et al. Acute bacterial meningitis in adults: a hospital based epidemiological study. *QJM* 1999;92:719-25.
 23. Tang LM, Chen ST, Hsu WC, et al. *Klebsiella* meningitis in Taiwan: an overview. *Epidemiol Infect* 1997;119:135-42.
 24. Lu CH, Chang WN, Chang HW. *Klebsiella* meningitis in adults: clinical features prognostic factors and therapeutic outcomes. *J Clin Neurosci* 2002;9:533-8.
 25. Huang CR, Lu CH, Chang HW, et al. Community-acquired spontaneous bacterial meningitis in adult diabetic patients: an analysis of clinical characteristics and prognostic factors. *Infection* 2002;30:346-50.
 26. Lee SS, Chen YS, Tsai HC, et al. Predictors of septic metastatic infection and mortality among patients with *Klebsiella pneumoniae* liver abscess. *Clin Infect Dis* 2008;47:642-50.
 27. Lu CH, Chang WN, Chuang YC, et al. Gram-negative bacillary meningitis in adult post-neurosurgical patients. *Surg Neurol* 1999;52:438-43.
 28. Chang WN, Chuang YC, Lu CH. *Acinetobacter* meningitis: four nosocomial cases. *J Formos Med Assoc* 1999;98:214-7.
 29. Chen SF, Chang WN, Lu CH, et al. Adult *Acinetobacter* meningitis and its comparison with non-*Acinetobacter* gram-negative bacterial meningitis. *Acta Neurol Taiwan* 2005;14:131-7.
 30. Huang CR, Lu CH, Chuang YC, et al. Adult *Pseudomonas aeruginosa* meningitis: high incidence of underlying medical and/or postneurosurgical conditions and high mortality rate. *Jpn J Infect Dis* 2007;60:397-9.
 31. Chuang YC, Chang WN, Lu CH, et al. *Pseudomonas aeruginosa* central nervous system infections: analysis of clinical features of 16 adult patients. *Chin Med J (Taipei)* 1999;62:300-7.
 32. Yang TM, Lu CH, Huang CR, et al. Clinical characteristics of adult *Escherichia coli* meningitis. *Jpn J Infect Dis* 2005;58:168-70.
 33. Huang CR, Lu CH, Chang WN. Adult *Enterobacter* meningitis: a high incidence of coinfection with other pathogens and frequent association with neurosurgical procedures. *Infection* 2001;29:75-9.
 34. Lu CH, Chang WN, Chang HW. Adult bacterial meningitis in southern Taiwan: epidemiologic trend and prognostic factors. *J Neurol Sci* 2000;182:36-44.
 35. Chang WN, Lu CH, Huang CR, et al. Mixed infection in adult bacterial meningitis. *Infection* 2000;28:8-12.
 36. Chang WN, Lu CH, Wu JJ, et al. *Staphylococcus aureus* meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains. *Infection* 2001;29:245-50.
 37. Chang WN, Lu CH, Huang CR, et al. Epidemiology of adult staphylococcal meningitis in southern Taiwan: a clinical comparison of *Staphylococcus aureus* infection and coagulase-negative staphylococcal infection. *Jpn J Infect Dis* 2007;60:262-6.
 38. Huang CR, Lu CH, Wu JJ, et al. Coagulase-negative staphylococcal meningitis in adults: clinical characteristics and therapeutic outcomes. *Infection* 2005;33:56-60.

39. Chang SC, Sun CC, Yang LS, et al. Increasing nosocomial infections of methicillin-resistant *Staphylococcus aureus* at a teaching hospital in Taiwan. *Int J Antimicrob Agents* 1997;8:109-14.
40. Wu JJ, Huang AH, Dai JH et al. Rapid detection of oxacillin-resistant *Staphylococcus aureus* in blood cultures by an impedance method. *J Clin Microbiol* 1997;35:1460-4.
41. Liao CH, Chen SY, Huang YT, et al. Outcome of patients with methicillin-resistant *Staphylococcus aureus* bacteraemia at an Emergency Department of a medical centre in Taiwan. *Int J Antimicrob Agents* 2008;32:326-32.
42. Lee LH, Chang WN, Huang CR, et al. Adult *Streptococcus pneumoniae* meningitis in southern Taiwan: epidemiologic trends and prognostic factors. *J Clin Neurosci* 2005;12:32-5.
43. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. *N Engl J Med* 2004;351:1849-59.
44. Swartz MN. Bacterial meningitis- a review of the past 90 years. *N Engl J Med* 2004;351:1826-8.
45. Coant PN, Kornberg AE, Duffy LC, et al. Blood culture results as determinants in the organism identification of bacterial meningitis. *Pediatr Emerg Care* 1992;8:200-5.
46. Steigbigel NH. Computed tomography of the head before a lumbar puncture in suspected meningitis- is it helpful? *N Engl J Med* 2001;345:1768-70.
47. Lu CH, Chang HW, Lui CC, et al. Cerebral haemodynamics in acute bacterial meningitis in adults. *QJM* 2006;99:863-9.
48. Zunt JR, Marra CM. Cerebrospinal fluid testing for the diagnosis of central nervous system infection. *Neurol Clin* 1999;17:675-89.
49. Pizon AF, Bonner MR, Wang HE, et al. Ten years of clinical experience with adult meningitis at an urban academic medical center. *J Emerg Med* 2006;30:367-70.
50. Coyle PK. Overview of acute and chronic meningitis. *Neurol Clin* 1999;17:691-710.
51. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004;39:1267-84.
52. Fishman RA. Studies of the transport of sugars between blood and cerebrospinal fluid in normal states and in meningeal carcinomatosis. *Trans Am Neurol Assoc* 1963;88:114-8.
53. Leib SL, Boscacci R, Gratzl Q, et al. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. *Clin Infect Dis* 1999;29:69-74.
54. Hussein AS, Shafran SD. Acute bacterial meningitis in adults. A 12-year review. *Medicine (Baltimore)* 2000;79:360-8.
55. Aminpour S, Tinling SP, Brodie HA. Role of tumor necrosis factor-alpha in sensorineural hearing loss after bacterial meningitis. *Otol Neurotol* 2005;26:602-9.
56. Lu JJ, Perng CL, Lee SY, et al. Use of PCR with universal primers and restriction endonuclease digestions for detection and identification of common bacterial pathogens in cerebrospinal fluid. *J Clin Microbiol* 2000;38:2076-80.
57. Saravolatz LD, Manzor O, Vandervelde N, et al. Broad-range bacterial polymerase chain reaction for early detection of bacterial meningitis. *Clin Infect Dis* 2003;36:40-5.
58. Deutch S, Pedersen LN, Podenphant L, et al. Broad-range real time PCR and DNA sequencing for the diagnosis of bacterial meningitis. *Scand J Infect Dis* 2006;38:27-35.
59. Fitch MT, van de Beek D. Emergency diagnosis and treatment of adult meningitis. *Lancet Infect Dis* 2007;7:191-200.
60. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002;347:1549-56.
61. van de Beek D, Weisfelt M, de Gans J, et al. Drug insight adjunctive therapies in adults with bacterial meningitis. *Nat Clin Pract Neurol* 2006;2:504-16.
62. Tofte RW, Peterson PK, Kim Y. Opsonic activity of normal human cerebrospinal fluid for selected bacterial species. *Infect Immun* 1979;26:1093-8.
63. Thea D, Barza M. Use of antibacterial agents in infections of central nervous system. *Infect Dis Clin North Am* 1989;3:553-70.
64. Ziai WC, Lewin JJ 3rd. Update in the diagnosis and management of central nervous system infections. *Neuro Clin* 2008;26:427-68.
65. Scheld WM, Koedel U, Nathan B, et al. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. *J Infect Dis* 2002;186:S225-33.
66. van de Beek D, de Gans J, McIntyre P, et al. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev* 2007;24:CD004405.

67. Hoffmann O, Priller J, Prozorovski T, et al. TRAIL limits excessive host immune responses in bacterial meningitis. *J Clin Invest* 2007;117:2004-13.
68. Mogensen TH, Berg RS, Paludan SR, et al. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by *Neisseria meningitidis* and *Streptococcus pneumoniae*. *Infect Immun* 2008;76:189-97.
69. Schut ES, de Gans J, van de Beek D. Community-acquired bacterial meningitis in adults. *Pract Neurol* 2008;8:8-23.
70. Chaudhuri A, Martinez-Martin P, Kennedy PG, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. *Eur J Neurol* 2008;15:649-59.
71. Scarborough M, Gordon SB, Whitty CJ, et al. Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. *N Engl J Med* 2007;357:2441-50.
72. Nguyen TH, Tran TH, Thwaites G, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. *N Engl J Med* 2007;357:2431-40.
73. Lutsar I, Friedland IR, Jafri HS, et al. Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. *J Antimicrob Chemother* 2003;52:651-5.
74. Cabellos C, Martinez-Lacasa J, Tubau F, et al. Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis. *J Antimicrob Chemother* 2000;45:315-20.
75. Thomas R, Le Tulzo Y, Bouget J, et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Adult Meningitis Steroid Group. *Intensive Care Med* 1999;25:475-80.
76. Richard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patient receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. *Clin Infect Dis* 2007;44:250-5.
77. Lu CH, Chang WN, Chuang YC, et al. The prognostic factors of adult gram-negative bacillary meningitis. *J Hosp Infect* 1998;40:27-34.
78. Lu CH, Chang WN, Chang HW, et al. The value of serial cerebrospinal fluid 14-3-3 protein levels in adult community-acquired bacterial meningitis. *QJM* 2008;101:225-30.